Detalles de la búsqueda
1.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709073
2.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38438627
3.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol
; 102(10): 2741-2752, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592092
4.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Ann Hematol
; 102(3): 547-561, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695874
5.
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Future Oncol
; 2022 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36416118
6.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950489
7.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34224180
8.
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(9): 2387-2398, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232360
9.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017044
10.
Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.
Int J Mol Sci
; 21(19)2020 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32992663
11.
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Genes Chromosomes Cancer
; 58(11): 747-755, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31135094
12.
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).
Haematologica
; 108(8): 2244-2248, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36601981
13.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Blood
; 126(3): 291-9, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25987659
14.
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
BMC Cancer
; 17(1): 852, 2017 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29241450
15.
Managing patients with myelofibrosis and low platelet counts.
Ann Hematol
; 96(4): 537-548, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27209535
16.
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Br J Haematol
; 175(5): 917-924, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714772
17.
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica
; 101(9): 1065-73, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27247324
18.
Correction to: Allogeneic hematopoietic stem cell transplantation improves longterm outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(11): 2877-2878, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529106
19.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med
; 366(9): 787-98, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22375970
20.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Blood
; 122(25): 4047-53, 2013 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24174625